Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma

PURPOSE: To report planned final overall (OS) and progression-free survival (PFS) analyses from the phase II PEAK trial (NCT00819780). METHODS: Patients with previously untreated, KRAS exon 2 wild-type (WT) metastatic colorectal cancer (mCRC) were randomised to mFOLFOX6 plus panitumumab or bevacizum...

Descripción completa

Detalles Bibliográficos
Autores principales: Rivera, Fernando, Karthaus, Meinolf, Hecht, J. Randolph, Sevilla, Isabel, Forget, Frédéric, Fasola, Gianpiero, Canon, Jean-Luc, Guan, Xuesong, Demonty, Gaston, Schwartzberg, Lee S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522523/
https://www.ncbi.nlm.nih.gov/pubmed/28424871
http://dx.doi.org/10.1007/s00384-017-2800-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522523/
https://www.ncbi.nlm.nih.gov/pubmed/28424871
http://dx.doi.org/10.1007/s00384-017-2800-1

Ejemplares similares